February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
4 citations
,
September 2024 in “BMC Cancer” 
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.
25 citations
,
April 2010 in “Clinical and Experimental Dermatology” Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
11 citations
,
May 2010 in “Journal of the South African Veterinary Association” Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
November 2011 in “Molecular Cancer Therapeutics” The Hedgehog signaling pathway is linked to cancer development, and targeting it with inhibitors shows promise but faces challenges like resistance.
12 citations
,
January 2011 in “Dermatologic Surgery” Retinoids can prevent skin cancer in high-risk people but have side effects and require more research on dosing and effectiveness.
15 citations
,
March 2015 in “Experimental Dermatology” Clotrimazole, an antifungal cream, may safely reduce skin pigmentation by breaking down the enzyme needed for making melanin.
29 citations
,
September 2017 in “Oncology and therapy” The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
March 2025 in “Nature Communications” NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
64 citations
,
February 2008 in “Cancer Research” Inactivating both p53 and Rb genes in mice speeds up aggressive skin cancer development.
58 citations
,
September 2019 in “EMBO Molecular Medicine” CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
2 citations
,
April 2022 in “Cutaneous and Ocular Toxicology” Tofacitinib may help treat hair loss in children with alopecia areata.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” This post hoc analysis of the ALLEGRO phase 2b/3 study evaluated the efficacy of ritlecitinib, an oral JAK3/TEC inhibitor, in patients with alopecia areata (AA) who did not meet target efficacy response criteria at Week 24. The study included patients aged 2-12 years with at least 50% scalp hair loss. Results showed that among those who did not respond by Week 24, 8-14% achieved a response by Week 28, increasing to 22-34% by Week 48. Similar improvements were observed for eyebrow and eyelash assessments. Ritlecitinib was well tolerated, with common adverse events including upper respiratory tract infection, nasopharyngitis, and headache. The findings suggest that continued ritlecitinib treatment may lead to hair regrowth in patients who initially do not respond.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
3 citations
,
April 2012 in “Cancer research” Mouse skin cancer progression involves a unique group of cells marked by ABCG2 and MTS24.
September 2023 in “Journal of the American Academy of Dermatology”